Status:
COMPLETED
This Study Investigates the Impact of Single Nucleotide Polymorphisms in Genes Involved in the Pharmacokinetics and Toxicity of Doxorubicin (DOX) in Egyptian Female Patients with Breast Cancer. It Also Aims to Explore the Association of Pretreatment Neutrophil to Lymphocyte Ratio to PCR
Lead Sponsor:
Menoufia University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-75 years
Brief Summary
This study aims to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in doxorubicin transport and metabolism on its pharmacokinetics and toxicity in Egyptian breast ca...
Detailed Description
Plasma concentrations of doxorubicin will be determined and venous blood samples will be obtained from each patient for SNP genotyping of genes involved in doxorubicin transport and metabolism on its ...
Eligibility Criteria
Inclusion
- Females aged ≥ 18 years
- Performance status 0 or 1
- No contraindication to chemotherapy
- Adequate bone marrow
- Adequate hepatic function
- Adequate renal function
Exclusion
- Poorly controlled diabetes mellitus
- Ischemic heart disease
- Uncontrolled hypertension
- Active infections
- Baseline ejection fraction \< 50%
- Performance status ≥ 2
- Pregnancy Lactation, bilateral breast cancer, male patients, primary surgery, distant metastases, other malignancies, inflammations, hematological disorders, autoimmune diseases, and patients taking non-steroidal anti-inflammatory drugs (NSAIDs), steroidal and antibiotic therapy.
Key Trial Info
Start Date :
October 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06595758
Start Date
October 1 2021
End Date
November 1 2023
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Menofia university
Shibīn al Kawm, Egypt